# Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

> **NCT07385989** · PHASE2 · NOT_YET_RECRUITING · sponsor: **WEI XU** · enrollment: 40 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma

## Interventions

- **DRUG:** Golidocitinib in combination with P-GEMOX and PD-1 inhibitor
- **DRUG:** PD-1 inhibitor in combination with P-GEMOX

## Key facts

- **NCT ID:** NCT07385989
- **Lead sponsor:** WEI XU
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-25
- **Primary completion:** 2028-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07385989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07385989, "Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07385989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*